Skip to content

DCGI greenlights Qdenga dengue vaccine for all age groups

By News Analysis India · · 1 min read

New Delhi, July 20 – India's drug regulator, the DCGI, has approved Takeda Pharmaceuticals' dengue vaccine Qdenga for use in people ranging from four to sixty years old. The approval eliminates the need for a pre‑vaccination dengue antibody test, making the vaccine accessible to anyone in the eligible age group, regardless of previous infection history.

Takeda said the clearance will bolster the nation's dengue mitigation efforts, especially as India remains among the world’s top countries for dengue cases and faces the spread of all four dengue virus serotypes in several states.

Since its 2022 launch, Qdenga is now authorized in 43 countries, with more than 32 million doses delivered worldwide. The Indian approval is underpinned by extensive clinical data, including over 28,000 participants in Phase 1‑3 trials across dengue‑affected and unaffected regions. Indian regulators examined outcomes from the local Phase 3 DEN‑302 study, which demonstrated robust safety and immunogenicity in the target age range.

Seven‑year follow‑up data show that Qdenga reduces the risk of severe dengue leading to hospitalisation across all serotypes. The vaccine regimen consists of two sub‑cutaneous injections given three months apart, each containing 0.5 mL of the formulation.

Company representatives noted that the vaccine’s availability will complement ongoing vector control, monitoring, and community‑engagement initiatives, forming a critical pillar of India's broader dengue control framework.